Figure 1From: Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results Virologic response (% of patients with HIV-1 RNA <50 copies/mL) over 96 weeks. Virologic response by screening HIV-1 RNA.Back to article page